Erlotinib Hydrochloride Tablets 150?mg (Loruit) – EGFR Tyrosine Kinase Inhibitor for Oncology
$23.00
Erlotinib Hydrochloride (brand name Loruit®), a selective EGFR tyrosine kinase inhibitor, blocks EGFR-driven tumor growth. Supplied as 150?mg tablets (7 per box), manufactured by Shanghai Chnuo Pharmaceutical Co., Ltd. (NMPA No.?H20193262; Code?86900647000183; barcode?6973850270074). Strictly for laboratory research use?Please consult the staff for other purposes?
描述
Erlotinib Hydrochloride Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Erlotinib Hydrochloride Tablets (Loruit®) |
| Generic Name | Erlotinib HCl |
| Dosage Form | Oral film-coated tablet |
| Strength | 150?mg per tablet |
| Packaging | 7 tablets per box |
| Approval Number (NMPA) | H20193262 |
| Product Code | 86900647000183 |
| Manufacturer | Shanghai Chnuo Pharmaceutical Co., Ltd. |
| Barcode | 6973850270074 |
| CAS Number | 183321?74?6 |
| Molecular Formula | C??H??N?O?·HCl |
| Molecular Weight | ~429.9?g/mol |
| Mechanism Class | EGFR tyrosine kinase inhibitor |
| Pharmacokinetics | ~59% oral bioavailability; ~95% protein binding; ~36?h half-life |
| Metabolism/Excretion | CYP3A4 metabolism; >90% feces, ~9% urine |
| Storage | Store at 15–30?°C, protect from moisture/light |
| Intended Use | Laboratory research only — Not for clinical or veterinary use |
Erlotinib Hydrochloride Mechanism of Action
Erlotinib reversibly binds the ATP-binding site of EGFR, inhibiting its autophosphorylation and downstream signaling (PI3K/Akt, RAS/RAF/MEK/ERK), which reduces tumor proliferation and survival. It’s effective against both wild-type and mutant EGFR in NSCLC and pancreatic models.pubmed.ncbi.nlm.nih.gov+5ncbi.nlm.nih.gov+5go.drugbank.com+5
Research & Pharmacology Context
-
Approved by China’s NMPA (HJ20170143) since 2019, mirroring global approvals in NSCLC and pancreatic cancer.
-
STATPEARLS summarizes its use as a first- to third-line therapy in EGFR?mutant NSCLC and in combination with gemcitabine for pancreatic cancer.
-
Clinically relevant pharmacokinetics: ~59% bioavailability, 36?h half-life, high protein binding—ideal for research dose modeling.
Research Applications
-
NSCLC and pancreatic cancer models, especially those with EGFR mutations
-
Kinase pathway assays targeting EGFR phosphorylation and downstream signals
-
Drug interaction studies involving CYP3A4 substrates/inhibitors
-
Resistance research comparing erlotinib with osimertinib or combination therapies
-
PK/PD modeling and biomarker exploration relating to rash or biologic response
?? Research?Use Disclaimer
This product is for laboratory research and development use only. Not intended for clinical, diagnostic, therapeutic, or veterinary use.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Limertinib Tablets 80?mg ×?20 – by Osscon Pharma | Research Use Only (3rd?Gen EGFR?TKI)
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR?TKI) at 80?mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M?mutated non?small cell lung cancer, including patients with brain metastases.
?? For research use only – Not for human consumption or therapeutic use. $1.00 -
Aprepitant Capsules (Kangrenping®) – 125?mg [For Laboratory Research Use Only]
Aprepitant Capsules (Kangrenping®), 125?mg ×1 + 80?mg ×2 per box. For laboratory research use only $1.00 -
Temozolomide Capsules 100?mg × 5 – ChuanNuo (MySean) | Research Grade Glioblastoma Drug
Temozolomide 100?mg capsules, 5?count box, produced by Shanghai ChuanNuo Pharmaceuticals Co., Ltd., approved under NMPA H20234716. A key alkylating agent for glioblastoma and astrocytoma research—ideal for preclinical oncology models.
?? For laboratory research or analytical use only – Not for human consumption or therapeutic use. $1.00 -
Pirtobrutinib Tablets (Jaypirca) – 100?mg × 14 Tablets × 4 Blisters Price comparison
Pirtobrutinib Tablets (brand name: Jaypirca) is the world’s first non-covalent BTK inhibitor, provided here as 100?mg oral film?coated tablets. Manufactured by Lilly del Caribe, Inc. and approved for import in China (NMPA No. HJ20240116; code 86978403001613). Supplied with clear indication for research/investigational use only, not for human therapeutic use. $2.00
评价
目前还没有评价